Which companies overlap with Pfizer's Upjohn has merged with Mylan to form Viatris Inc.'s portfolio?

Top competitors by shared drug class: Tri-Service General Hospital, AstraZeneca, Eli Lilly and Company, Merck Sharp & Dohme LLC, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. pipeline: 21 marketed, 0 filed, 12 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

21 marketed 0 filed 12 Phase 3 3 Phase 2 31 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Doxazosin mysylate GITS	Doxazosin mysylate GITS	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor	Cardiovascular; Urology
Oxybutynin ER	Oxybutynin ER	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M3)	Urology / Neurology
ziprazidone	ziprazidone	marketed			Other
Blood samples for the analysis of sildenafil in plasma	Blood samples for the analysis of sildenafil in plasma	marketed
Lyrica (pregabalin)	Lyrica (pregabalin)	marketed	Gabapentinoid; anticonvulsant; anxiolytic	Alpha-2-delta subunit of voltage-gated calcium channels	Neurology; Pain Management; Psychiatry
Xalatan	Xalatan	marketed		Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor	Cardiovascular
Atorvastatin and Omega-3 fatty acids	Atorvastatin and Omega-3 fatty acids	marketed
Xalacom	Xalacom	marketed			Other
pregabalin and celecoxib	pregabalin and celecoxib	marketed
tolterodine SR, overactive bladder	tolterodine SR, overactive bladder	marketed
latanoprost 0.005% ophthalmic solution	latanoprost 0.005% ophthalmic solution	marketed
Non-selective NSAIDS	Non-selective NSAIDS	marketed	Non-selective NSAID	COX-1 and COX-2	Pain Management, Rheumatology, Cardiovascular

Therapeutic area mix

Other · 5
Neurology; Pain Management; Psychiatry · 3
Ophthalmology · 3
Cardiovascular · 3
Urology · 2
Neurology · 2
Psychiatry · 2
Rheumatology / Pain Management · 1
Urology / Cardiovascular · 1
Urology / Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Tri-Service General Hospital · 3 shared drug classes
AstraZeneca · 3 shared drug classes
Eli Lilly and Company · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Massachusetts General Hospital · 2 shared drug classes
Medical University of Vienna · 2 shared drug classes
CHU de Quebec-Universite Laval · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Pfizer's Upjohn has merged with Mylan to form Viatris Inc.:

Cite this brief

Drug Landscape (2026). Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc. Accessed 2026-05-17.